rate contract for group no.4, injection, i.v.fluids, solutions. tender for the supplies of drugs and pharmaceuticals, labchemicals, x ray films and chemicals, surgicalsutures and dressings, vaccines, sera etc. and general items for the year 2023 25. , inj: 17 hydroxy progesterone caproate500 mg. , inj: 17 hydroxy progesterone caproate 250 mg , inj: acyclovir 250 mg. , inj: adenosine 6mg/2ml , inj: adrenaline 1:1000 , inj: amino acid 10% , infusion: amio acid solution i.v , inj: amiodarone 150 mg/3ml , inj: anti diptheria serrum 10,000 i.u. vial , inj: anti rabies-human rabies immunoglobin 2ml (300 i.u.) pfs , inj: anti rabies-immune serum - 300 iu/ml (equine) immunoglobin , inj: anti rabies-monoclonal antibodies , inj: anti snake serum(polyvalent) , inj: benzathine penicilline 12 lakhs , inj: betamethasone 4 mg. , inj: calcium gluconate (10% w/v) , inj: carboprost tromethamine 250 mcg/ml , inj: carboprost tromethamine125 mcg/ml , inj: ceftriaxone sodium 1000 mg + disodium edetate 37 mg + sulbactum 500 mg , inj: ceftriaxone sodium 1000 mg + disodium edetate 74 mg + sulbactum 1000 mg , inj: dexamethasone sod. phosphate 4 mg/ ml. , iv fluid: dextose 5% in fractional saline 0.45% (ffs technology) - each 100 ml. contains - dextrose anhydrous ip 5.0 gm. + sodium chloride ip 0.45 gm. +water for inj ip qs. , iv fluid: dextrose inj ip 10% (ffs technology) - each 100 ml. contains - dextrose anhydrous ip 10.0 gm.+ water for inj ip qs. , iv fluid: dextrose inj ip 25% (ffs technology) - each 100 ml. contains - dextrose anhydrous ip 25.0 gm.+ water for inj ip qs. , inj: diazepam 5 mg/ ml , inj: diclofenac sod,. 25 mg/ ml , inj: diclofenac sodium 75 mg/ml, 1ml inj iv bolus, surfactant free inj , inj: dicyclomine 10 mg/ ml , inj: dobutamine hcl 250 mg/ vial , inj: dopamine 200 mg/ amp.. (40 mg./ml.) , inj: drotaverine 20 mg/ml , inj: drotaverine 40 mg , insulin: dulagutide 1.5mg , inj: each 0.9ml contains: atosiban acetateip equivalent to atosiban 6.75 mgwater for inj ipq.s. , inj: each 0.9ml contains:atosiban acetateip equivalent to atosiban 37.5 mgwater for inj ip q.s. , inj: each ml contains human insulin ip 100 iu (30% as soluble insulin inj and 70% as isophane insulin inj) (human insulin of recombinant dna origin) , inj: each ml contains human insulin ip 100 iu (human insulin of recombinant dna origin) , inj: each ml contains human insulin ip 100 iu (insulin, human of recombinant dna origin) inj , inj: each ml contains human insulin ip 40 iu (30% as soluble insulin inj and 70% as isophane insulin inj) (human insulin of recombinant dna origin) inj , inj: each ml contains human insulin ip 40 iu (human insulin of recombinant dna origin) , inj: each ml contains insulin glargine (rdna origin) 100 iu , inj: each ml contains insulin glargine (rdna origin) 100 iu , inj: each ml contains insulin glargine (rdna origin) 100 iu , inj: each ml of 50% insulin lispro and 50%insulin lispro protamine suspension contins 100 i.u. (equivalent to 3.5 mg) insulin lispro i.p. (r-dna origin) , inj: each ml of insulin lispro contains 100 i.u. (equivalent to 3.5 mg) insulin lispro i.p. (r-dna origin) , inj: enoxaparin in prefilledsyringe in strength of 0.4 ml , inj: enoxaparin in prefilledsyringe in strength of 0.6 ml , inj: erythropoitin 2000 units(recombinant (human) , inj: erythropoitin 4000 units(recombinant (human) , inj: ethamsylate 125 mg/ ml , inj: etophylline 169. 4 mg + theophylline 50.6 mg per 2 ml. amp. , inj: ferric carboxymaltose ( elemental iron- 50 mg/ml) , inj: fondaparinoaux 2.5 mg , inj: frusemide 10 mg/ml. , inj: hepatitis b surface antigen recombinant/ 20 mcg/ ml. , infusion: human albumin 20% , inj: human chorionicgonadotropin 5000 iu (hormone) , inj: hydrocortisone sod.succinate 100 mg/ ml. , inj: hyoscinebutyl bromide 20 mg/ ml , inj: insulin aspart 100 iu/ml. (insulin analogue short acting) , inj: insulin aspart 100u/ml for inj in 10ml , inj: insulin aspart 100u/ml for inj in 3ml , inj: insulin glargine 100units/ml , inj: insulin lispro 25% + lispro protamine 75% , inj: iron sucrose 100 mg , inj: isoxsuprine 5 mg/ ml , inj: labetalol 5 mg per ml. , inj: magnesium sulphate 50%2 ml / amp , iv fluid: mannitol inj ip 20% (ffs technology) - each 100 ml. contains: - mannitol usp 20.00gm. + water for inj ip q.s. , inj : mecobalamine 500mcg , inj: methylergometrine maleate 0.2 mg/ ml , inj: methylprednisolone 500 mg , inj: metoclopromide 5 mg/ ml , inj: multivitamin iv containing vit. c 500 mg + vit.a 10000 iu + vit. d 1000 iu + b1 50 mg + b2 14 mg+ b6 15 mg + nicotinamide 100 mg/ 10 ml vial , inj: ondansetron2mg/ml. , inj: oxytocin iv 5iu , infusion: paracetamol 1000mg/100ml , inj: paracetamol 150 mg/ ml , inj: pentoprazole 40 mg , inj: pheneramine maleate 22.75 mg/ ml , inj: ranitidine hcl 50mg/ 2 ml , inj: recombinant anti rho-d immunoglobulin 300 mcg/ml , inj: recombinant human growth hormone (somatropin) 4 i.u. + solvent for recosrtuction (water for inj 1ml) , inj: reteplase 10 units (18 mg.) (powder) , inj: reteplase-non-glycosylatedtissue plasminogen activator (tpa), 10 units with diluent and syringe , inj: rituximab 500mg/vial 50 ml , inj: secukinumab , inj: tenecteplase 40mg / vial usfda/emea approved , inj: terlipressin 1mg/10ml , inj: tocilizumab 80 mg/4 ml , inj : tranexamic acid 500 mg/5 ml , inj: triamcinolone acetonide 10mg/ml , inj: triamcinolone acetonide 40mg/ml , inj: vasopression 20 iu/ml , inj: vit d-3, 600000 unit /ml in oil base , inj: water for inj ip (sterile)